Hansjörg Wyss Department of Plastic and Reconstructive Surgery, New York University School of Medicine, 430 East 29th Street, New York, NY 10016, USA.
J Diabetes Res. 2017;2017:4826724. doi: 10.1155/2017/4826724. Epub 2017 Aug 20.
Despite improvements in awareness and treatment of type II diabetes mellitus (TIIDM), this disease remains a major source of morbidity and mortality worldwide, and prevalence continues to rise. Oxidative damage caused by free radicals has long been known to contribute to the pathogenesis and progression of TIIDM and its complications. Only recently, however, has the role of the Nrf2/Keap1/ARE master antioxidant pathway in diabetic dysfunction begun to be elucidated. There is accumulating evidence that this pathway is implicated in diabetic damage to the pancreas, heart, and skin, among other cell types and tissues. Animal studies and clinical trials have shown promising results suggesting that activation of this pathway can delay or reverse some of these impairments in TIIDM. In this review, we outline the role of oxidative damage and the Nrf2/Keap1/ARE pathway in TIIDM, focusing on current and future efforts to utilize this relationship as a therapeutic target for prevention, prognosis, and treatment of TIID.
尽管 II 型糖尿病(TIIDM)的认识和治疗有所改善,但这种疾病仍然是全球发病率和死亡率的主要原因,其患病率仍在继续上升。自由基引起的氧化损伤长期以来一直被认为是导致 TIIDM 及其并发症发病和进展的原因。然而,直到最近,Nrf2/Keap1/ARE 主抗氧化途径在糖尿病功能障碍中的作用才开始被阐明。越来越多的证据表明,该途径与糖尿病对胰腺、心脏和皮肤等其他细胞类型和组织的损伤有关。动物研究和临床试验已经显示出有希望的结果,表明激活该途径可以延缓或逆转 TIIDM 中的一些损伤。在这篇综述中,我们概述了氧化损伤和 Nrf2/Keap1/ARE 途径在 TIIDM 中的作用,重点介绍了目前和未来利用这种关系作为预防、预后和治疗 TIID 的治疗靶点的努力。